Tandem Diabetes Care, Inc. is a medical device company that designs, manufactures, and markets advanced automated insulin delivery systems for people with insulin-dependent diabetes. The company's core product portfolio includes the t:slim X2 insulin pump, which features a high-resolution color touchscreen, and the ultra-compact Tandem Mobi system. These durable devices are powered by the company's proprietary Control-IQ technology, an advanced hybrid closed-loop algorithm that integrates with continuous glucose monitors (CGMs) to predict glucose levels and automatically adjust insulin delivery. In addition to its hardware, Tandem generates recurring revenue through the sale of disposable infusion sets and cartridges that must be replaced every few days. While the majority of its revenue is derived from the United States, the company has been expanding its international footprint across other developed markets. Tandem competes in the diabetes care market by emphasizing consumer-focused design, software connectivity, and remote update capabilities that allow users to access new features without purchasing new hardware.
